Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its executive management team's participation in two investor conferences. The Cowen 42nd Annual Virtual Healthcare Conference is scheduled for March 9, 2022, at 2:50 p.m. ET, while the Oppenheimer’s 32nd Annual Healthcare Conference will take place on March 16, 2022, at 1:20 p.m. ET. Interested parties can access the live webcasts on the Aurinia corporate website under the Investors section.

Aurinia is focused on treating serious diseases, having launched LUPKYNIS™, the first FDA-approved oral therapy for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a 60% increase in Q4 2021 net revenue to $23.4 million and a full-year revenue of $45.6 million. The company achieved notable growth in LUPKYNIS patient starts and maintained a strong cash position of $466.1 million as of December 31, 2021. For 2022, Aurinia projects net revenue guidance of $115-$135 million, driven by positive results from the AURORA 2 study. With confirmed payor coverage exceeding 90% in the U.S., Aurinia is well-positioned for ongoing progress amid a robust product launch.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its fourth quarter and year-end 2021 financial results on February 28, 2021, before markets open. A conference call/webcast will be held at 8:30 am ET to discuss the results and the company's outlook for 2022. Aurinia focuses on therapies for serious diseases with high unmet needs, having launched the first FDA-approved oral treatment for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced its participation in the 11th Annual Leerink Global Healthcare Conference, scheduled from February 14-18, 2022. The company's corporate presentation will take place virtually on February 16, 2022, at 8 am ET. Interested participants can listen to the presentation by registering through a public link or by visiting the Investor section of Aurinia's corporate website. Aurinia is focused on developing therapies for serious diseases with high unmet medical needs, notably introducing the first FDA-approved oral therapy for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced participation in two virtual investor conferences. The H.C. Wainwright Virtual BioConnect 2022 Conference will feature an on-demand presentation from January 10 to January 13, 2022. Additionally, the J.P. Morgan 40th Annual Healthcare Conference will host a presentation on January 13, 2022, at 9:45 am EST. Interested individuals can access these presentations via the 'Investors' section on the Aurinia corporate website, which also provides further details on the company's focus in the biopharmaceutical industry.

Aurinia Pharmaceuticals (NASDAQ:AUPH) announced positive topline results from the AURORA 2 study, evaluating LUPKYNIS™ (voclosporin) for lupus nephritis treatment. The study showed a favorable risk/benefit profile and sustained efficacy over three years. Notably, the voclosporin-treated group maintained stable renal function and exhibited significant reductions in proteinuria compared to mycophenolate mofetil (MMF) and low-dose corticosteroids. Safety parameters were comparable, with no unexpected safety signals. The company will hold a conference call on December 9 at 8:30 a.m. EST.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will present at the 2021 Jefferies London Healthcare Conference from November 16-19, 2021. The on-demand presentation will be available starting on November 18 at 8 am GMT/3 am EST and will remain accessible until November 19 at 5 pm GMT/12 pm EST. Interested parties can access the webcast via the Aurinia corporate website's Investor section. Aurinia focuses on developing therapies for serious diseases with high unmet medical needs and has introduced the first FDA-approved oral therapy for adults with active lupus nephritis.

Aurinia Pharmaceuticals reported net revenue of $14.7 million for Q3 2021, a 122% increase from Q2. For the nine months ended September 30, 2021, total revenue reached $22.2 million. The company maintains its annual revenue estimate of $40 to $50 million. Aurinia registered steady growth in patient start forms and improved conversion rates, now at 68%. New pipeline additions include AUR200 and AUR300. The company reported a net loss of $50.3 million for Q3. Cash and equivalents stood at $286.4 million as of September 30, 2021.

Aurinia Pharmaceuticals announced updated interim results from the AURORA 2 study of LUPKYNIS for lupus nephritis treatment. The findings show sustained safety and tolerability, with patients experiencing significant reductions in proteinuria at 30 months, while renal function remained stable. The study's results will be presented at the American College of Rheumatology Convergence 2021. LUPKYNIS is the first FDA-approved oral therapy for active lupus nephritis, fulfilling a critical need in treating this serious condition.